QNRX
Quoin Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · US
$3.95
+0.51%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.93
From 52W high−82.29%
Volume5027.00
Market cap$18.98M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.93
From 52W high
−82.29%
Volume
5027.00
Market cap
$18.98M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
35.2
MomentumView details →
1D Return
+0.51%
YTD Return
−73.32%
SummaryUpdated Jun 1, 2026
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is a specialty pharmaceutical company founded in 2016 and based in Ashburn, Virginia. The company focuses exclusively on developing therapeutic products for rare and orphan diseases, particularly rare skin conditions that affect small patient populations with significant unmet medical needs. Since its initial public offering in August 2016, Quoin has concentrated its efforts on advancing a pipeline of topical treatments through clinical development, with its lead candidate targeting Netherton Syndrome, an extremely rare genetic skin disorder.
Similar companies
Latest newsMore news →
Quoin Pharmaceuticals announced that it will release its third-quarter 2026 financial results on November 5, 2026.6d agoQuoin Pharmaceuticals announced that a peer-reviewed paper introducing QRX003 and its mechanism of action in Netherton syndrome was accepted for publication in Dermatology and Therapy.29d agoThe U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Quoin Pharmaceuticals' QRX003 for the treatment of Peeling Skin Syndrome, the second such designation for the drug after a prior one for Netherton Syndrome.57d ago